📊 ARVN Key Takeaways
Is Arvinas, Inc.. (ARVN) a Good Investment?
Arvinas is a pre-commercial biotech company with minimal revenue ($15.6M) relative to massive operating losses ($63.8M), burning $70.5M annually in free cash flow. While the balance sheet is strong with $87.3M cash and minimal debt, the company has less than 1.2 years of cash runway at current burn rates with no clear path to profitability visible in current financials.
Arvinas shows mixed fundamentals: revenue is essentially flat, but net loss and diluted EPS improved materially year over year, indicating better operating efficiency and non-cash or partnership-related support. The balance sheet is strong with high liquidity and minimal debt, but the business still posts deeply negative operating margins and very weak free cash flow, so the core fundamental case depends on whether it can convert pipeline progress into more durable revenue and lower cash burn.
Arvinas, Inc.. Key Strengths (ARVN)
- Strong balance sheet with $87.3M cash and essentially debt-free capital structure
- Excellent liquidity position (5.44x current ratio) provides operational flexibility
- Improving loss metrics year-over-year (EPS improved 58.8% YoY shows cost management progress)
- Substantial stockholder equity base ($386.8M) provides downside protection
- Very strong liquidity with a 4.92x current and quick ratio
- Minimal leverage with only $0.6M of long-term debt against $433.9M of equity
- Net income loss narrowed significantly year over year, showing improving bottom-line trend
ARVN Stock Risks: Arvinas, Inc.. Investment Risks
- Severe cash burn of $70.5M annually against only $15.6M revenue indicates unsustainable operations
- Limited cash runway of approximately 1.2 years at current burn rate without additional funding
- Extreme negative profitability metrics (operating margin -409%, net margin -369.2%) indicate core business dysfunction
- Operating losses 4x larger than annual revenue with no demonstrated progress toward breakeven
- Typical biotech execution risk: success depends entirely on clinical trial outcomes and regulatory approvals not reflected in current financials
- Operating model remains unprofitable with a -45.1% operating margin
- Free cash flow is deeply negative at -$275.7M, indicating substantial ongoing cash burn
- Revenue declined slightly year over year, raising concern about growth durability and quality
Key Metrics to Watch
- Cash burn rate and operating cash flow - must show meaningful deceleration or additional funding
- Revenue growth and new product contributions - current $15.6M base is insufficient to sustain operations
- Operating expense trends - management must demonstrate ability to right-size cost structure
- Clinical development milestones and regulatory progress from pipeline candidates
- Whether company announces major funding round, partnership, or acquisition activity before cash depletes
- Operating cash burn and free cash flow trend
- Revenue growth quality and operating margin improvement
Arvinas, Inc.. (ARVN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.44x current ratio provides a solid financial cushion.
ARVN Profit Margin, ROE & Profitability Analysis
ARVN vs Healthcare Sector: How Arvinas, Inc.. Compares
How Arvinas, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Arvinas, Inc.. Stock Overvalued? ARVN Valuation Analysis 2026
Based on fundamental analysis, Arvinas, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Arvinas, Inc.. Balance Sheet: ARVN Debt, Cash & Liquidity
ARVN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Arvinas, Inc..'s revenue has grown significantly by 227% over the 5-year period, indicating strong business expansion. The most recent EPS of $-6.62 indicates the company is currently unprofitable.
ARVN Revenue Growth, EPS Growth & YoY Performance
ARVN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $15.6M | -$57.6M | $-0.90 |
| Q3 2021 | $20.3M | -$30.8M | N/A |
| Q2 2021 | $11.1M | -$25.2M | N/A |
| Q1 2021 | $5.5M | -$21.7M | N/A |
| Q3 2020 | $19.5M | -$17.7M | N/A |
| Q2 2020 | $12.0M | -$17.2M | N/A |
| Q1 2020 | $6.2M | -$14.4M | N/A |
| Q3 2019 | $13.4M | -$13.4M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Arvinas, Inc.. Dividends, Buybacks & Capital Allocation
ARVN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Arvinas, Inc.. (CIK: 0001655759)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ARVN
What is the AI rating for ARVN?
Arvinas, Inc.. (ARVN) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 77% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ARVN's key strengths?
Claude: Strong balance sheet with $87.3M cash and essentially debt-free capital structure. Excellent liquidity position (5.44x current ratio) provides operational flexibility. ChatGPT: Very strong liquidity with a 4.92x current and quick ratio. Minimal leverage with only $0.6M of long-term debt against $433.9M of equity.
What are the risks of investing in ARVN?
Claude: Severe cash burn of $70.5M annually against only $15.6M revenue indicates unsustainable operations. Limited cash runway of approximately 1.2 years at current burn rate without additional funding. ChatGPT: Operating model remains unprofitable with a -45.1% operating margin. Free cash flow is deeply negative at -$275.7M, indicating substantial ongoing cash burn.
What is ARVN's revenue and growth?
Arvinas, Inc.. reported revenue of $15.6M.
Does ARVN pay dividends?
Arvinas, Inc.. does not currently pay dividends.
Where can I find ARVN SEC filings?
Official SEC filings for Arvinas, Inc.. (CIK: 0001655759) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ARVN's EPS?
Arvinas, Inc.. has a diluted EPS of $-0.90.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ARVN's fundamental grade?
Based on our AI fundamental analysis in June 2026, Arvinas, Inc.. has a C grade with 77% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ARVN stock overvalued or undervalued?
Valuation metrics for ARVN: ROE of -14.9% (sector avg: 15%), net margin of -369.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ARVN's AI grade for 2026?
Our dual AI analysis gives Arvinas, Inc.. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ARVN's free cash flow?
Arvinas, Inc..'s operating cash flow is $-69.2M, with capital expenditures of $1.3M. FCF margin is -451.9%.
How does ARVN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -369.2% (avg: 12%), ROE -14.9% (avg: 15%), current ratio 5.44 (avg: 2).